Acadia Healthcare (NASDAQ:ACHC) Stock Rating Cut to Outperform at Raymond James Financial

Key Points

• Raymond James downgraded Acadia Healthcare from “strong buy” to “outperform,” while maintaining a $39 price target—about 38.8% above the stock’s cited price of $28.09.
• Analyst sentiment is mixed: eight analysts rate ACHC a Buy, five a Hold, and two a Sell, resulting in a consensus “Hold” rating and average price target of $30.69.
• Acadia exceeded quarterly estimates with $0.38 in EPS versus $0.35 expected and $865.84 million in revenue versus $844.19 million forecast, although revenue declined 0.4% year over year and net margin remained negative.

Acadia Healthcare (NASDAQ:ACHC - Get Free Report) was downgraded by analysts at Raymond James Financial from a "strong-buy" rating to an "outperform" rating in a report issued on Monday, Marketbeat Ratings reports. They currently have a $39.00 price target on the stock. Raymond James Financial's price objective would indicate a potential upside of 38.84% from the company's current price.

Other analysts have also issued research reports about the stock. Leerink Partners raised their price target on shares of Acadia Healthcare from $30.00 to $33.00 and gave the company a "market perform" rating in a research report on Wednesday, September 23rd. TD Cowen increased their target price on shares of Acadia Healthcare from $30.00 to $36.00 and gave the stock a "buy" rating in a research note on Tuesday, July 14th. Jefferies Financial Group upgraded Acadia Healthcare from a "hold" rating to a "buy" rating and raised their target price for the company from $24.50 to $30.00 in a research report on Wednesday, June 3rd. Barclays upped their price target on Acadia Healthcare from $25.00 to $32.00 and gave the stock an "equal weight" rating in a report on Thursday, July 30th. Finally, UBS Group raised their price objective on Acadia Healthcare from $31.00 to $39.00 and gave the company a "buy" rating in a report on Thursday, July 9th. Eight research analysts have rated the stock with a Buy rating, five have given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average target price of $30.69.

Acadia Healthcare Price Performance

Shares of ACHC opened at $28.09 on Monday. The stock's 50-day moving average price is $29.74 and its 200-day moving average price is $27.36. The company has a quick ratio of 1.57, a current ratio of 1.57 and a debt-to-equity ratio of 1.20. The company has a market capitalization of $2.62 billion, a price-to-earnings ratio of -2.26, a PEG ratio of 9.05 and a beta of 0.62. Acadia Healthcare has a 52 week low of $11.43 and a 52 week high of $35.83.

Acadia Healthcare (NASDAQ:ACHC - Get Free Report) last announced its quarterly earnings results on Tuesday, July 28th. The company reported $0.38 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.35 by $0.03. The company had revenue of $865.84 million during the quarter, compared to the consensus estimate of $844.19 million. Acadia Healthcare had a positive return on equity of 6.19% and a negative net margin of 33.44%.Acadia Healthcare's revenue for the quarter was down .4% on a year-over-year basis. During the same period in the previous year, the company posted $0.83 earnings per share. Acadia Healthcare has set its FY 2026 guidance at 1.450-1.600 EPS. On average, sell-side analysts predict that Acadia Healthcare will post 1.55 EPS for the current year.

Institutional Investors Weigh In On Acadia Healthcare

Institutional investors have recently bought and sold shares of the company. BlackRock Inc. purchased a new position in shares of Acadia Healthcare in the second quarter valued at approximately $441,685,000. Jefferies Financial Group Inc. purchased a new stake in shares of Acadia Healthcare during the second quarter worth approximately $106,458,000. Vaughan Nelson Investment Management L.P. acquired a new position in Acadia Healthcare in the 1st quarter valued at $43,017,000. Deutsche Bank AG purchased a new position in Acadia Healthcare in the 2nd quarter valued at $49,746,000. Finally, Invenomic Capital Management LP lifted its holdings in Acadia Healthcare by 71.0% in the 4th quarter. Invenomic Capital Management LP now owns 3,312,043 shares of the company's stock valued at $46,998,000 after purchasing an additional 1,375,647 shares in the last quarter.

About Acadia Healthcare

Acadia Healthcare Company, Inc is a provider of behavioral healthcare services. The company operates facilities that offer treatment for mental health conditions, substance use disorders and other behavioral health needs. Its services are designed for children, adolescents and adults and may include inpatient psychiatric care, residential treatment, outpatient programs and specialized care.

Acadia's facilities provide a range of treatment programs, including psychiatric hospitals, addiction treatment centers, eating disorder programs and other specialty behavioral healthcare services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.